Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward?
Publication
, Journal Article
Crowley, MJ; Maciejewski, ML
Published in: JAMA
July 3, 2018
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
July 3, 2018
Volume
320
Issue
1
Start / End Page
38 / 39
Location
United States
Related Subject Headings
- Insulin, Long-Acting
- Insulin, Isophane
- Insulin Glargine
- Insulin
- Hypoglycemic Agents
- Humans
- Glycated Hemoglobin
- General & Internal Medicine
- Diabetes Mellitus, Type 2
- Blood Glucose
Citation
APA
Chicago
ICMJE
MLA
NLM
Crowley, M. J., & Maciejewski, M. L. (2018). Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? JAMA, 320(1), 38–39. https://doi.org/10.1001/jama.2018.8033
Crowley, Matthew J., and Matthew L. Maciejewski. “Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward?” JAMA 320, no. 1 (July 3, 2018): 38–39. https://doi.org/10.1001/jama.2018.8033.
Crowley MJ, Maciejewski ML. Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? JAMA. 2018 Jul 3;320(1):38–9.
Crowley, Matthew J., and Matthew L. Maciejewski. “Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward?” JAMA, vol. 320, no. 1, July 2018, pp. 38–39. Pubmed, doi:10.1001/jama.2018.8033.
Crowley MJ, Maciejewski ML. Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? JAMA. 2018 Jul 3;320(1):38–39.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
July 3, 2018
Volume
320
Issue
1
Start / End Page
38 / 39
Location
United States
Related Subject Headings
- Insulin, Long-Acting
- Insulin, Isophane
- Insulin Glargine
- Insulin
- Hypoglycemic Agents
- Humans
- Glycated Hemoglobin
- General & Internal Medicine
- Diabetes Mellitus, Type 2
- Blood Glucose